Developing safe, effective, and orally available treatments for heavy metal poisoning (CRADA Final Report)

Sonsteng, Melanie, Rees, Julian · 2026

Read Developing safe, effective, and orally available treatments for heavy metal poisoning (CRADA Final Report) by Sonsteng, Melanie, Rees, Julian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/doe-osti-3023633-developing-safe-effective-and-orally-ava.txt.

Introduction

Lawrence Berkeley National Laboratory and HOPO Therapeutics closed CRADA FP00017846 with this short final summary, report LBNL-2001752, dated March 18, 2026. Melanie Sonsteng was the lab contact. Under the Cyclotron Road program, sponsored by Activate with 100,000 dollars plus an in-kind gift, the team studied metal chelating agents. The work covered how the agents bind, move, deliver, and remove metal ions, and what that could mean for poisoning care, cleanup, and energy uses. It mapped binding across ions and worked on formulation and dosing strategies, and lists no publications or inventions.

Catalog record

CREATORSonsteng, Melanie, Rees, Julian
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEDOE OSTI

Source: https://www.osti.gov/biblio/3023633

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cooperative Research and Development Agreement (CRADA) Final Report

Report Date: 3-18-26

Parties to the Agreement: Lawrence Berkeley National Laboratory and HOPO
Therapeutics, Inc.

CRADA number: FP00017846

CRADA Title: Developing safe, effective, and orally available treatments for heavy
metal poisoning

Responsible Technical Contact at Berkeley Lab: Melanie Sonsteng

Name and Email Address of POC at Partner Company(ies):
Julian Rees [email protected]

Sponsoring DOE Program Office(s): N/A, sponsored by Activate, Inc.

LBNL Report Number: LBNL-2001752

Joint Work Statement Funding Table showing DOE funding commitment:
 non-DOE Funding to LBNL (Activate $100,000
sponsored)
 Participant Funding to LBNL $0
 Participant In-Kind Contribution Value $100,000
 Total of all Contributions $200,000

Provide a list of publications, conference papers, or other public releases of results,
developed under this CRADA:
N/A

Provide a detailed list of all subject inventions, to include patent applications,
copyrights, and trademarks:
None

Executive Summary of CRADA Work:

As part of the Cyclotron Road program, HOPO Therapeutics investigated the technical
capabilities of heavy metal chelating agents for the sequestration, (re)distribution, delivery,
and removal of metal ions, and their applications in the health, environment, and energy
sectors. The project team researched chelating agents for use in the removal of heavy

metals, and evaluated their potential benefits for a range of therapeutic, environmental, and
energy applications.

Summary of Research Results:

The project team explored the complete range of heavy metal binding properties for
relevant ions, and the development of formulation, dosing, and application strategies that
can optimize an intended therapeutic benefit or other desired outcome. The research
assessed the decorporation efficacy of chelating agents for removal of bismuth, lead,
gadolinium, and other heavy metals and determined the decorporation efficacy of chelating
agents for removal of a mixture of heavy metals. The team explored methods to optimize
efficacy of chelation and sequestration for chelating agents delivered via a range of
formulation and dosing methods and evaluated additional applications of chelation agents

Read the complete text